Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 3/20 | 0.64 |
| ▸ | NAAA | Q02083 | 1/20 | 0.64 |
| ▸ | CNR1 | P21554 | 9/20 | 0.53 |
| ▸ | CNR2 | P34972 | 6/20 | 0.52 |
| ▸ | LDHA | P00338 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | RBP1 | P09455 | 1/20 | 0.43 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23776171 | 1.00 | DAGLA (0.64) | DAGLANAAACNR1CNR2LDHA | |
| SCHEMBL23992550 | 0.85 | CNR1 (0.52) | DAGLANAAACNR1CNR2TRPV1 | |
| SCHEMBL25819129 | 0.82 | DAGLA (0.67) | DAGLANAAACNR1CNR2TRPV1 | |
| SCHEMBL25819101 | 0.82 | DAGLA (0.67) | DAGLANAAACNR1CNR2TRPV1 | |
| SCHEMBL25260080 | 0.82 | DAGLA (0.81) | DAGLANAAACNR1CNR2LDHA | |
| SCHEMBL18179105 | 0.80 | DAGLA (0.63) | DAGLANAAACNR1CNR2TRPV1 | |
| SCHEMBL22046217 | 0.80 | DAGLA (0.63) | DAGLANAAACNR1CNR2TRPV1 | |
| SCHEMBL18371589 | 0.80 | CNR2 (0.58) | DAGLANAAACNR1CNR2LDHA | |
| SCHEMBL18371588 | 0.80 | CNR2 (0.58) | DAGLANAAACNR1CNR2LDHA | |
| SCHEMBL16769851 | 0.80 | CNR2 (0.58) | DAGLANAAACNR1CNR2LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220280582-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | SINDERBRAND LAW GROUP, PC | 2022-09-08 | — | — | US | disclosed |
| US-11344591-B2 | Pharmaceutical composition and method of manufacturing | SINDERBRAND LAW GROUP, PC | 2022-05-31 | — | — | US | disclosed |
| US-11331358-B2 | Pharmaceutical composition and method of manufacturing | SINDERBRAND LAW GROUP, PC | 2022-05-17 | — | — | US | disclosed |
| US-20200246406-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CURE PHARMACEUTICAL HOLDING CORP. (US) | 2020-08-06 | — | — | US | disclosed |
| US-20200246405-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CURE PHARMACEUTICAL HOLDING CORP. (US) | 2020-08-06 | — | — | US | disclosed |
| US-20200215137-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CURE PHARMACEUTICAL HOLDING CORP. (US) | 2020-07-09 | — | — | US | disclosed |
| US-20200197466-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CURE PHARMACEUTICAL HOLDING CORP (US) | 2020-06-25 | — | — | US | disclosed |
| US-10639339-B2 | Pharmaceutical composition and method of manufacturing | CURE PHARMACEUTICAL HOLDING CORP. (US) | 2020-05-05 | — | — | US | disclosed |
| US-10624940-B2 | Pharmaceutical composition and method of manufacturing | CURE PHARMACEUTICAL HOLDING CORP. (US) | 2020-04-21 | — | — | US | disclosed |
| US-20190209633-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | SINDERBRAND LAW GROUP, PC | 2019-07-11 | — | — | US | disclosed |
| US-20160074451-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | SINDERBRAND LAW GROUP, PC | 2016-03-17 | — | — | US | disclosed |
| US-20160074451-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | SINDERBRAND LAW GROUP, PC | 2016-03-17 | — | — | US | disclosed |
| US-9186386-B2 | Pharmaceutical composition and method of manufacturing | SINDERBRAND LAW GROUP, PC | 2015-11-17 | — | — | US | disclosed |
| US-9186386-B2 | Pharmaceutical composition and method of manufacturing | SINDERBRAND LAW GROUP, PC | 2015-11-17 | — | — | US | disclosed |
| US-20150297653-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | SINDERBRAND LAW GROUP, PC | 2015-10-22 | — | — | US | disclosed |
| US-20150297653-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | SINDERBRAND LAW GROUP, PC | 2015-10-22 | — | — | US | disclosed |
| US-20150297654-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | SINDERBRAND LAW GROUP, PC | 2015-10-22 | — | — | US | disclosed |
| US-20150297654-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | SINDERBRAND LAW GROUP, PC | 2015-10-22 | — | — | US | disclosed |
| US-9044390-B1 | Pharmaceutical composition and method of manufacturing | SINDERBRAND LAW GROUP, PC | 2015-06-02 | — | — | US | disclosed |
| US-9044390-B1 | Pharmaceutical composition and method of manufacturing | SINDERBRAND LAW GROUP, PC | 2015-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200246406-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CNR2, CNR1, CYP3A5 | DAGLA 223/4885NAAA 1650/4885CNR1 2/4885 |
| US-20200246405-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CNR2, CNR1, CYP3A5 | DAGLA 223/4885NAAA 1650/4885CNR1 2/4885 |
| US-10639339-B2 | Pharmaceutical composition and method of manufacturing | CNR2, CNR1, CYP3A5 | DAGLA 223/4885NAAA 1650/4885CNR1 2/4885 |
| US-20200215137-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CNR2, CNR1, CYP3A5 | DAGLA 223/4885NAAA 1650/4885CNR1 2/4885 |
| US-11344591-B2 | Pharmaceutical composition and method of manufacturing | CNR2, CNR1, CYP3A5 | DAGLA 223/4885NAAA 1650/4885CNR1 2/4885 |
| US-11331358-B2 | Pharmaceutical composition and method of manufacturing | CNR2, CNR1, CYP3A5 | DAGLA 223/4885NAAA 1650/4885CNR1 2/4885 |
| US-20160074451-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CNR2, CNR1, CYP3A5 | DAGLA 223/4885NAAA 1650/4885CNR1 2/4885 |
| US-20150297654-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CNR2, CNR1, CYP3A5 | DAGLA 223/4885NAAA 1650/4885CNR1 2/4885 |
| US-20220280582-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CNR2, CNR1, CYP3A5 | DAGLA 223/4885NAAA 1650/4885CNR1 2/4885 |
| US-20150297653-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CNR2, CNR1, CYP3A5 | DAGLA 223/4885NAAA 1650/4885CNR1 2/4885 |
| US-20200197466-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CNR2, CNR1, CYP3A5 | DAGLA 223/4885NAAA 1650/4885CNR1 2/4885 |
| US-20190209633-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CNR2, CNR1, CYP3A5 | DAGLA 223/4885NAAA 1650/4885CNR1 2/4885 |
| US-10624940-B2 | Pharmaceutical composition and method of manufacturing | CNR2, CNR1, CYP3A5 | DAGLA 223/4885NAAA 1650/4885CNR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.